Compare GSK plc (GSK) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Philip Morris International Inc. — how do they compare? GSK plc trades at $52.68 (market cap $101.34B), while Philip Morris International Inc. trades at $186.88 (market cap $281.91B). The key difference: Philip Morris International Inc. is far larger — about 2.8× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | PM | |
|---|---|---|
Market Cap | $101.34B | $281.91B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $191.86 |
52-Week Low | $36.20 | $144.33 |
Enterprise Value | $121.95B | $328.41B |
Dividend Yield | 3.49% | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Philip Morris International (PM) trades at $175.95, down 2.35% amid a bearish technical signal and recent profit forecast revision. The company reported strong Q1 2026 EPS of $1.96, beating estimates, but faces headwinds from a $500 million impairment charge and margin pressures. Revenue growth remains steady, with 2025 revenue at $40.65 billion and net income margin of 26.74%. Analyst consensus is bullish with a $194 price target, though technical indicators show resistance near $179.
The stock presents a mixed outlook: solid fundamentals and high analyst buy ratings support upside potential, but near-term risks include cost pressures, currency volatility, and illicit market growth. Long-term investors may find value in the dividend and brand strength, while caution is warranted due to regulatory and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
